We recently compiled a list of the 10 Best Foreign Stocks With Dividends For Passive Income. In this article, we are going to ...

We expect Novo to gain $75 billion of a more than $200 billion global GLP-1 market in diabetes and obesity by 2031, ahead of semaglutide's 2032 patent expiration, with Lilly standing as the firm's key ...

It sells products through independent distributors primarily in India.Sanofi Indias products viz. Lantus, Combiflam, Amaryl and Allegra feature in the top 100 pharmaceutical brands in India.

Sanofi-Synthélabo is known for creating meningitis treatment, Menactra, diabetes treatment Lantus, colorectal cancer drug Eloxatin, and lung, prostate and breast cancer drug Taxorete. While this ...

One of the key priorities for Witz is a successful launch for Lantus follow-up Toujeo, which hinges on whether Sanofi can make a compelling case for switching patients currently taking Lantus to ...

Ozempic and other glucagon-like peptide-1 (GLP-1) agonists are a transformative new class of medicines for the treatment of ...

It has its own manufacturing facility at Goa. It sells products through independent distributors primarily in India.Sanofi India's products viz. Lantus Combiflam Amaryl and Allegra feature in the top ...

vial or cartridge Lantus vial or cartridge (Sanofi-Aventis) 28 days Prescribing information 70% insulin aspart protamine suspension and 30% insulin as part injection (rDNA origin) pen fill ...

The remarkable efficacy of new diabetes and weight loss medicines like Ozempic and Mounjaro have been one of the biggest health stories of recent years. Despite rising rates of diabetes and obesity, ...

Immunology superstar Dupixent, which first brought Regeneron and Sanofi together in 2007, has entered its megablockbuster era. But even as the billions pile up, Regeneron isn't entirely happy with ...